Dr Mark Cooksey – CEO & Managing Director – ABx Group (ASX:ABX) is a uniquely positioned, Australian company delivering materials for a cleaner future. The two current areas of focus are the creation of an ionic adsorption clay rare earth project in northern Tasmania and the establishment of a plant to produce hydrogen fluoride and aluminium fluoride from recycled industrial waste, to replace imports (ALCORE).
Copyright 2024 – Finance News Network
30 November 2022 - James Powell, the General Manager - Investor Relations, Corporate Affairs and Sustainability of the Rural Funds Group Limited (ASX:RFF) presents on the group's FY22 financial results.
30 Jul 2021 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, provides an update on activities from the company's June quarter, discussing growth in platforms and infrastructure and the recent capital raise.
28 Feb 2024 - Oliver Kiddie - Managing Director - Legend Mining is an Australian exploration company listed on the Australian Securities Exchange (ASX:LEG). Legend’s mission is to make value-adding mineral discoveries and utilise all available asset bases to maximise stakeholder benefit.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
01 Oct 2024 - Hazer Group Limited (ASX:HZR) CEO Glenn Corrie provides an update on the company, discussing IP protection and moving into commercialisation.
17 May 2024 - Elementos Limited (ASX:ELT) Managing Director Joe David discusses the recommencement of DFS and licensing activities following discussions with the Andalusian government.
21 Jun 2021 - BluGlass Limited (ASX:BLG) Executive Chair, James Walker and Chief Technology and Operations Officer, Dr Ian Mann discuss the company's laser diode production and its recent rights issue.
28 Aug 2019 - Noxopharm Limited (ASX:NOX) CEO Dr Greg van Wyk discusses the company's anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
